Glenmark Pharmaceuticals is currently trading at Rs 859.90, up by 6.40 points or 0.75% from its previous closing of Rs 853.50 on the BSE.
The scrip opened at Rs. 860.00 and has touched a high and low of Rs. 866.35 and Rs. 853.55 respectively. So far 10812 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.
Last one week high and low of the scrip stood at Rs. 892.40 and Rs. 849.70 respectively. The current market cap of the company is Rs. 24277.58 crore.
The promoters holding in the company stood at 46.48% while Institutions and Non-Institutions held 41.92% and 11.60% respectively.
Glenmark Pharmaceuticals has launched an offer on the Singapore Stock Exchange to raise up to $200 million through issue of securities. The Mumbai-based company has decided on a regulatory floor price for conversion of the FCCBs at Rs 861.84. JP Morgan Securities is the sole global coordinator and book-runner for the said issue.
Last year, the company’s board and shareholders had approved a plan to raise funds up to $500 million through issuance of securities, including shares or equity-linked assets, convertible bonds, warrants, and depository receipts.
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1677.10 |
| Dr. Reddys Lab | 1238.10 |
| Cipla | 1238.70 |
| Zydus Lifesciences | 942.95 |
| Lupin | 2327.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: